Comparative Pharmacology
Head-to-head clinical analysis: FAMVIR versus VITRASERT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FAMVIR versus VITRASERT.
FAMVIR vs VITRASERT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Famciclovir is a prodrug that is rapidly converted to penciclovir, which inhibits viral DNA polymerase by competing with deoxyguanosine triphosphate, thereby inhibiting viral DNA synthesis and replication.
Vitrasert (ganciclovir implant) releases ganciclovir, a nucleoside analog that inhibits cytomegalovirus (CMV) replication by competitively inhibiting viral DNA polymerase (UL54) after intracellular phosphorylation to ganciclovir triphosphate. This results in chain termination and viral DNA synthesis inhibition.
250 mg orally three times daily for 7 days for herpes zoster; 125 mg orally twice daily for 5 days for recurrent genital herpes; 250 mg orally twice daily for 7 days for first-episode genital herpes; 500 mg orally twice daily for 7 days for herpes zoster in immunocompromised patients; 500 mg orally twice daily for 7 days for recurrent mucocutaneous herpes in HIV patients.
Intravitreal implant containing 0.59 mg fluocinolone acetonide; inserted into the vitreous cavity; releases drug over approximately 36 months; no systemic dosing.
None Documented
None Documented
Terminal elimination half-life of penciclovir is approximately 2–3 hours in patients with normal renal function; extends to 9–18 hours in severe renal impairment (CrCl <30 mL/min).
Terminal half-life of 2.8 hours following intravitreal injection; sustained local levels for 2-3 weeks.
Renal: 60–70% as penciclovir via tubular secretion and glomerular filtration; fecal: <10%; biliary: <1%.
Primarily biliary/fecal (approximately 90%) with minimal renal excretion (<10% unchanged in urine).
Category C
Category C
Antiviral
Antiviral